CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1

Abstract Circular RNAs (circRNAs) play critical roles in clear cell renal cell carcinoma (ccRCC). However, their involvement in sunitinib resistance remains largely unknown. Herein, we identified a novel circRNA, named circME1, which contributes to sunitinib resistance development in ccRCC. CircME1...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2022-08, Vol.41 (33), p.3979-3990
Main Authors: Zhang, Ming-xiao, Wang, Jia-li, Mo, Cheng-qiang, Mao, Xiao-peng, Feng, Zi-hao, Li, Jia-ying, Lin, Hai-shan, Song, Hong-de, Xu, Quan-hui, Wang, Ying-han, Lu, Jun, Wei, Jin-huan, Han, Hui, Chen, Wei, Mao, Hai-ping, Luo, Jun-hang, Chen, Zhen-hua
Format: Article
Language:English
Subjects:
Cell growth
Cell proliferation
Clear cell-type renal cell carcinoma
Gene expression
Glycolysis
Growth factors
Investigations
Kidney cancer
Kinases
Medical prognosis
Metastasis
Phenotypes
Ribonucleoproteins (small nuclear)
Survival analysis
Targeted cancer therapy
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Circular RNAs (circRNAs) play critical roles in clear cell renal cell carcinoma (ccRCC). However, their involvement in sunitinib resistance remains largely unknown. Herein, we identified a novel circRNA, named circME1, which contributes to sunitinib resistance development in ccRCC. CircME1 also promoted proliferation, migration, and invasion of ccRCC cells. Further mechanism analysis showed that circME1 interacted with U1 snRNP at the promoter of its parental gene ME1, thereby upregulating the expression of ME1, enhancing aerobic glycolysis of ccRCC, and promoting its malignant phenotype. Furthermore, ME1 specific inhibitor could effectively repress the oncogenic functions of circME1. Taken together, our study demonstrates that the circME1/ME1 pathway is involved in ccRCC progression and sunitinib resistance development, which may be exploited for anticancer therapy.
ISSN:0950-9232
1476-5594
DOI:10.1038/s41388-022-02386-8